Comparative Pharmacology
Head-to-head clinical analysis: NEXIUM IV versus OMEPRAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXIUM IV versus OMEPRAZOLE.
NEXIUM IV vs OMEPRAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Esomeprazole is the S-isomer of omeprazole, which is concentrated in the acidic environment of parietal cells and converted to the active sulfenamide form that binds covalently with the proton pump, leading to irreversible inhibition.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
20-40 mg intravenously once daily; for GERD with erosive esophagitis: 20-40 mg once daily; for Zollinger-Ellison syndrome: 80 mg IV every 12 hours, adjust based on acid output.
20-40 mg orally once daily before a meal for 4-8 weeks.
None Documented
None Documented
Clinical Note
moderateEsomeprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Esomeprazole."
Clinical Note
moderateOmeprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Omeprazole."
Clinical Note
moderateEsomeprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole."
Clinical Note
moderateTerminal elimination half-life is approximately 1-1.5 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class A, B, or C), half-life may be prolonged up to 2.9-8 hours.
Terminal elimination half-life is approximately 0.5–1 hour. However, the pharmacodynamic effect (gastric acid suppression) lasts much longer due to irreversible binding to the proton pump. The half-life is prolonged in patients with hepatic impairment (up to 3–4 hours in cirrhosis) and in CYP2C19 poor metabolizers (up to 2–3 hours).
Renal (approx. 80% as inactive metabolites), fecal (approx. 20% as metabolites and parent drug). Less than 1% excreted unchanged in urine.
Approximately 77% of a dose is excreted in urine (as metabolites, including hydroxyomeprazole and the corresponding carboxylic acid and sulfone derivatives), and about 18% is eliminated in feces via biliary excretion. Less than 1% of the parent drug is excreted unchanged in urine.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor
Omeprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole."